A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC

NCT06977828 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

40

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Non-small Cell Lung Cancer)
Neoadjuvant Immunotherapy
Adjuvant Immunotherapy

Interventions

DRUG: tislelizumab in combination with anlotinib and platinum-based doublet chemotherapy

Sponsor

The First Affiliated Hospital with Nanjing Medical University